Tg Therapeutics Stock Fundamentals
| TGTX Stock | USD 40.84 3.78 10.20% |
TG Therapeutics fundamentals help investors to digest information that contributes to TG Therapeutics' financial success or failures. It also enables traders to predict the movement of TGTX Stock. The fundamental analysis module provides a way to measure TG Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to TG Therapeutics stock.
TGTX |
TG Therapeutics Company Return On Equity Analysis
TG Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current TG Therapeutics Return On Equity | 0.12 |
Most of TG Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, TG Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, TG Therapeutics has a Return On Equity of 0.1222. This is 100.51% lower than that of the Biotechnology sector and 100.34% lower than that of the Health Care industry. The return on equity for all United States stocks is 139.42% lower than that of the firm.
TG Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining TG Therapeutics's current stock value. Our valuation model uses many indicators to compare TG Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across TG Therapeutics competition to find correlations between indicators driving TG Therapeutics's intrinsic value. More Info.TG Therapeutics is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers reporting about 0.47 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for TG Therapeutics is roughly 2.11 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the TG Therapeutics' earnings, one of the primary drivers of an investment's value.TGTX Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses TG Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of TG Therapeutics could also be used in its relative valuation, which is a method of valuing TG Therapeutics by comparing valuation metrics of similar companies.TG Therapeutics is currently under evaluation in return on equity category among its peers.
TGTX Fundamentals
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0578 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.28 % | ||||
| Current Valuation | 5.79 B | ||||
| Shares Outstanding | 157.07 M | ||||
| Shares Owned By Insiders | 9.41 % | ||||
| Shares Owned By Institutions | 62.89 % | ||||
| Number Of Shares Shorted | 25.74 M | ||||
| Price To Earning | (4.14) X | ||||
| Price To Book | 26.30 X | ||||
| Price To Sales | 17.69 X | ||||
| Revenue | 329 M | ||||
| Gross Profit | 290.52 M | ||||
| EBITDA | 49.9 M | ||||
| Net Income | 23.38 M | ||||
| Cash And Equivalents | 195.71 M | ||||
| Cash Per Share | 1.45 X | ||||
| Total Debt | 253.72 M | ||||
| Debt To Equity | 0.62 % | ||||
| Current Ratio | 4.68 X | ||||
| Book Value Per Share | 1.54 X | ||||
| Cash Flow From Operations | (40.52 M) | ||||
| Short Ratio | 14.83 X | ||||
| Earnings Per Share | 0.15 X | ||||
| Target Price | 42.83 | ||||
| Number Of Employees | 338 | ||||
| Beta | 2.3 | ||||
| Market Capitalization | 5.82 B | ||||
| Total Asset | 577.69 M | ||||
| Retained Earnings | (1.53 B) | ||||
| Working Capital | 475.68 M | ||||
| Current Asset | 71.33 M | ||||
| Current Liabilities | 16.88 M | ||||
| Net Asset | 577.69 M |
About TG Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze TG Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TG Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TG Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York. Tg Therapeuticscmn operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 173 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for TGTX Stock Analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.